肿瘤防治研究2025，Vol.52Issue(6)：429-435,7.DOI:10.3971/j.issn.1000-8578.2025.24.1209
EGFR阳性非小细胞肺癌EGFR-TKI耐药后的治疗现状及未来展望
Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
摘要
Abstract
EGFR-mutant non-small cell lung cancer(NSCLC)is a common type of lung cancer,with EGFR tyrosine kinase inhibitors(EGFR-TKIs)being the standard first-line treatment.However,most patients with NSCLC eventually develop resistance to EGFR-TKIs.Studies on the mechanism underlying EGFR-TKI resistance have driven the development of personalized and precision medicine.Current strategies to address resistance include targeted therapy,immunotherapy,and novel drug treatments.Selecting the appropriate personalized treatment plan is crucial for improving the survival rate and quality of life of patients with EGFR-mutant NSCLC.Thus,this study provides a brief review of the current status and future perspectives in the treatment of EGFR-mutant NSCLC after progression on EGFR-TKI therapy.关键词
EGFR突变阳性非小细胞肺癌/EGFR-TKI耐药/靶向治疗/免疫治疗/新型药物Key words
EGFR-mutant NSCLC/EGFR-TKI resistance/Targeted therapy/Immunotherapy/Novel drugs分类
临床医学引用本文复制引用
曾壹铭,方文峰,张力..EGFR阳性非小细胞肺癌EGFR-TKI耐药后的治疗现状及未来展望[J].肿瘤防治研究,2025,52(6):429-435,7.基金项目
National Natural Science Foundation of China(No.82241232,82272789) 国家自然科学基金(82241232,82272789) （No.82241232,82272789）
